Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer

Rudolf M Huber; Diego Kauffmann-Guerrero

doi:10.1097/CCO.0000000000001110

Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer

Curr Opin Oncol. 2024 Nov 4. doi: 10.1097/CCO.0000000000001110. Online ahead of print.

Authors

Rudolf M Huber¹, Diego Kauffmann-Guerrero

Affiliation

¹ Ludwig-Maximilians-Universität München (LMU), University hospitals, Department of Medicine V, Division of Respiratory Medicine and Thoracic Oncology, Thoracic Oncology Centre Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.

PMID: 39526694
DOI: 10.1097/CCO.0000000000001110

Abstract

Purpose of review: Immune checkpoint inhibitors (ICIs) and targeted therapies have changed the landscape of management of nonsmall cell lung cancer (NSCLC) dramatically. Whereas ICIs in NSCLC without specific driver mutations are well established it is unclear what the place of ICIs in driver mutation-positive NSCLC is. This review summarizes the current view on the use of ICIs in driver mutation-positive NSCLC.

Recent findings: Immune checkpoint inhibition in combination with chemotherapy (and antiangiogenesis) in recurrent driver mutation-positive NSCLC after tyrosine kinase inhibitor therapy may be effective.

Summary: Currently the role of immune checkpoint inhibitors in driver mutation-positive NSCLC is limited. They can in combination be applied in second and later line settings if no specific therapy is available.